News Updates

More Articles Back to Article

CHMP recommends deucravacitinib for plaque psoriasis

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the use of Bristol Myers Squibb's Sotyktu, or deucravacitinib, as a treatment for moderate-to-severe cases of plaque psoriasis. The recommendation was based on data from a Phase 3 trial that showed Sotyktu resulted in clinically significant improvements in terms of skin clearance and symptom burden as well as quality of life measures in comparison to placebo plus Otezla, or apremilast. PMLive (UK) (1/30)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!